Pathophysiology of bone cancer pain.

The most common cancers, such as those affecting the breast, prostate, and lung have a strong predilection to metastasize to bone. Bone metastasis frequently results in pain, pathologic fractures, hypercalcemia, and spinal cord compression. Pain can have a devastating effect on the quality of life in advanced cancer patients and is a serious complication of cancer. Although significant advances are being made in cancer treatment and diagnosis, the basic neurobiology of bone cancer pain is poorly understood. New insights into the mechanisms that induce cancer pain now are coming from animal models. Chemicals derived from tumor cells, inflammatory cells, and cells derived from bone appear to be involved simultaneously in driving this frequently difficult-to-control pain state. Understanding the mechanisms involved in the pathophysiology of bone cancer pain will improve both our ability to provide mechanism-based therapies and the quality of life of cancer patients.

[1]  Z. Wiesenfeld‐Hallin,et al.  Effects of intrathecal morphine, clonidine and baclofen on allodynia after partial sciatic nerve injury in the rat , 1999, Acta anaesthesiologica Scandinavica.

[2]  H. Abu‐Saad,et al.  The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain , 2001, Pain.

[3]  Growth factors and their receptors in metastasis. , 1991, Seminars in cancer biology.

[4]  P. Seifert,et al.  Tumours may be innervated , 2001, Virchows Archiv.

[5]  F. J. Alvarez,et al.  Nociceptors for the 21st Century , 2000, Current review of pain.

[6]  O. Krishtal,et al.  Cationic channels activated by extracellular atp in rat sensory neurons , 1988, Neuroscience.

[7]  I. Nagy,et al.  Noxious heat activates all capsaicin-sensitive and also a sub-population of capsaicin-insensitive dorsal root ganglion neurons , 1999, Neuroscience.

[8]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Lazdunski,et al.  The Acid-sensitive Ionic Channel Subunit ASIC and the Mammalian Degenerin MDEG Form a Heteromultimeric H+-gated Na+ Channel with Novel Properties* , 1997, The Journal of Biological Chemistry.

[10]  R. Yezierski,et al.  The role of neuroinflammation and neuroimmune activation in persistent pain , 2001, Pain.

[11]  M. Schultzberg,et al.  Substance P- and CGRP-immunoreactive nerves in bone , 1988, Peptides.

[12]  L. Radbruch,et al.  Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology , 2001, Pain.

[13]  G. Davar.  Endothelin-1 and metastatic cancer pain. , 2001, Pain medicine.

[14]  J. Rothstein,et al.  Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. , 1992, The New England journal of medicine.

[15]  J. Rothstein,et al.  Altered expressions of glutamate transporter subtypes in rat model of neonatal cerebral hypoxia-ischemia. , 2001, Brain research. Developmental brain research.

[16]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  Paul J. Williams,et al.  The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. , 2001, Cancer research.

[18]  Paul J. Williams,et al.  Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma , 2000, Cancer.

[19]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[20]  C. Woolf,et al.  Neuropathic pain: aetiology, symptoms, mechanisms, and management , 1999, The Lancet.

[21]  L. King,et al.  Role of epidermal growth factor in carcinogenesis. , 1986, Cancer research.

[22]  Steven W. Martin,et al.  A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.

[23]  S. Perkins,et al.  Review of Cellular Mechanisms of Tumor Osteolysis , 2000, Clinical orthopaedics and related research.

[24]  R. DuBois,et al.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. , 1996, Gastroenterology.

[25]  S. Simon,et al.  The activation mechanism of rat vanilloid receptor 1 by capsaicin involves the pore domain and differs from the activation by either acid or heat. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Kress,et al.  Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin , 2000, The Journal of Neuroscience.

[27]  G. Hans,et al.  Behavioral signs of acute pain produced by application of endothelin‐1 to rat sciatic nerve , 1998, Neuroreport.

[28]  P. Mantyh,et al.  Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur , 2002, Neuroscience.

[29]  P. Mantyh,et al.  Expression and Localization of Endothelin Receptors: Implications for the Involvement of Peripheral Glia in Nociception , 2001, The Journal of Neuroscience.

[30]  J. Griffiths.  Are cancer cells acidic? , 1991, British Journal of Cancer.

[31]  E. Torebjörk,et al.  Novel classes of responsive and unresponsive C nociceptors in human skin , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  S. Adami,et al.  New Bisphosphonates in the Treatment of Bone Diseases , 1999, Drugs & aging.

[33]  I. Taylor,et al.  Angiogenesis in cancer: the role of endothelin-1. , 1999, Annals of the Royal College of Surgeons of England.

[34]  E. Mccleskey,et al.  Chemical mediators of pain due to tissue damage and ischemia. , 2000, Progress in brain research.

[35]  M. T. Brewer,et al.  Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia , 1995, Brain Research.

[36]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[37]  P. Mantyh,et al.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.

[38]  D. Julius,et al.  The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.

[39]  A. Basbaum,et al.  Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. , 1995, Science.

[40]  M. Rowbotham,et al.  Oral opioid therapy for chronic peripheral and central neuropathic pain. , 2003, The New England journal of medicine.

[41]  R MELZACK,et al.  The perception of pain. , 1961, Scientific American.

[42]  P. Yarnold,et al.  IL-1β AND TNF-α IN PROSTATIC SECRETIONS ARE INDICATORS IN THE EVALUATION OF MEN WITH CHRONIC PROSTATITIS , 2000 .

[43]  W. Daughaday,et al.  Tumor secretion of growth factors. , 1991, Endocrinology and metabolism clinics of North America.

[44]  S. Mercadante,et al.  Breakthrough pain in cancer patients: pathophysiology and treatment. , 1998, Cancer treatment reviews.

[45]  Steven F. Maier,et al.  Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states , 1995, Pain.

[46]  A. Basbaum,et al.  Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  X. Ortiz-González,et al.  An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats , 1998, Neuroreport.

[48]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Bevan,et al.  Protons: small stimulants of capsaicin-sensitive sensory nerves , 1994, Trends in Neurosciences.

[50]  F. Sinicrope,et al.  Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. , 1999, Cancer research.

[51]  R. Beauchamp,et al.  TGF‐β and colorectal carcinogenesis , 2001 .

[52]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[53]  C. Galasko,et al.  Diagnosis of skeletal metastases and assessment of response to treatment. , 1995, Clinical orthopaedics and related research.

[54]  R E Coleman,et al.  Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases , 2001, Cancer.

[55]  R. Elde,et al.  Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites , 1999, The European journal of neuroscience.

[56]  R. Treede,et al.  Inhibition of rapid heat responses in nociceptive primary sensory neurons of rats by vanilloid receptor antagonists. , 1999, Journal of neurophysiology.

[57]  A. Lipton,et al.  Oral bisphosphonates , 2000, Cancer.

[58]  S. Santavirta,et al.  Innervation of bone from healthy and arthritic rats by substance P and calcitonin gene related peptide containing sensory fibers. , 1992, The Journal of rheumatology.

[59]  Paul Jacobsen,et al.  Breakthrough pain: characteristics and impact in patients with cancer pain , 1999, Pain.

[60]  A. Bjurholm.  Neuroendocrine peptides in bone , 2004, International Orthopaedics.

[61]  Martin Koltzenburg,et al.  Molecular mechanisms of cancer pain , 2002, Nature Reviews Cancer.

[62]  W. Ichikawa,et al.  Depth of invasion parallels increased cyclooxygenase‐2 levels in patients with gastric carcinoma , 2001, Cancer.

[63]  B F Boyce,et al.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. , 1995, Cancer research.

[64]  S. Mercadante.  Malignant bone pain: pathophysiology and treatment , 1996, Pain.

[65]  A. Basbaum,et al.  The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.

[66]  Qingyuan Yang,et al.  Increased cyclooxygenase‐2 (cox‐2) expression and activity in a murine model of metastatic breast cancer , 2001, International journal of cancer.

[67]  F. Fulfaro,et al.  The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials , 1998, Pain.

[68]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[69]  P. Mantyh,et al.  Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. , 2002, Cancer research.

[70]  T. Engber,et al.  Multiple actions of systemic artemin in experimental neuropathy , 2003, Nature Medicine.

[71]  J. Mönkkönen,et al.  Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.

[72]  T. Terada,et al.  S‐100‐positive nerve fibers in hepatocellular carcinoma and intrahepatic cholangiocarcinoma: An immunohistochemical study , 2001, Pathology international.

[73]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[74]  P. Dellemijn.  Are opioids effective in relieving neuropathic pain? , 1999, Pain.

[75]  P. Mantyh,et al.  Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain , 1999, The Journal of Neuroscience.

[76]  L. Terenius,et al.  Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. , 1988, Journal of the autonomic nervous system.

[77]  S. Barron,et al.  Weakness in malignancy: Evidence for a remote effect of tumor on distal axons , 1978, Annals of neurology.

[78]  O. S. Nielsen,et al.  Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  S. Landis,et al.  Developmental Changes in the Transmitter Properties of Sympathetic Neurons That Innervate the Periosteum , 2000, The Journal of Neuroscience.

[80]  L. Huang,et al.  Peripheral Inflammation Sensitizes P2X Receptor-Mediated Responses in Rat Dorsal Root Ganglion Neurons , 2002, The Journal of Neuroscience.

[81]  Atsushi Tokunaga,et al.  Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury , 2000, Molecular and Cellular Neuroscience.

[82]  G. Burnstock,et al.  Progressive loss of perivascular nerves adjacent to colorectal cancer. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[83]  L. Djouhri,et al.  Association of somatic action potential shape with sensory receptive properties in guinea‐pig dorsal root ganglion neurones , 1998, The Journal of physiology.

[84]  A. Basbaum,et al.  Molecular mechanisms of nociception , 2001, Nature.

[85]  S. McMahon.  NGF as a mediator of inflammatory pain. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[86]  M. Vasko,et al.  Prostaglandin-induced neuropeptide release from spinal cord. , 1995, Progress in brain research.

[87]  C. Woolf,et al.  Neuronal plasticity: increasing the gain in pain. , 2000, Science.

[88]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[89]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[90]  A I Basbaum,et al.  Impaired nociception and pain sensation in mice lacking the capsaicin receptor. , 2000, Science.

[91]  R. Roberts,et al.  Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. , 2001, Neoplasia.

[92]  S. Felten,et al.  Noradrenergic and peptidergic innervation of the mouse femur bone marrow. , 1996, Acta histochemica.